Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 April;157(2) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 April;157(2):31-6

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

ORIGINAL ARTICLES   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 1998 April;157(2):31-6

Copyright © 1998 EDIZIONI MINERVA MEDICA

language: English

Clinical effectiveness of a prolonged-release form of oral diclofenac sodium in the treatment of some non-articular rheumatisms

Mattioli P. L. 1, Palazzini E. 2

1 University of Reggio Calabria, School of Medicine, Chair of Internal Medicine, Policlinico Mater Domini - Catanzaro; 2 Medical Department - Alfa Wassermann SpA, Bologna


PDF


Methods. ­Forty ­patients suf­fering ­from radic­u­litis (30 ­cases) and fibro­myo­sitis (10 ­cases) ­were ­treated ­with 150 mg of ­oral diclof­enac ­sodium/day for 30 ­days. Two dif­fering ­posology ­schemes ­were ­applied to ­patients: one ­group (15 ­cases ­with radic­u­litis and 5 ­with fibro­myo­sitis) was admin­is­tered ­daily one con­trolled-­release cap­sule con­taining 150 mg of the ­NSAID ­under ­study; the ­other ­group (15 ­with radic­u­litis and 5 ­with fibro­myo­sitis) was admin­is­tered one ­enteric-­coated ­tablet con­taining 50 mg of diclof­enac ­sodium ­every 8 ­hours. ­Drug effec­tive­ness was mon­i­tored ­during treat­ment reg­is­tering the ­changes in VAS ­values and ­symptom ­scores, as ­well as in ­some labor­a­tory ­tests (ESR, C-reac­tive pro­tein, ­Rheuma ­test); ­drug ­safety was con­trolled ­through the rou­tine labor­a­tory ­tests of ­systemic tol­er­ability and by ­checking ­local tol­er­ance at the gas­troin­tes­tinal ­level.
­Results. The ­same ­dosage reg­imen pro­duced, in the two ­groups, ­very sim­ilar effi­cacy ­results: inten­sity of ­pain and ­severity of the ­other symp­toms and ­signs ­were ­clearly and pro­gres­sively ­reduced ­without sta­tis­ti­cally sig­nif­i­cant dif­fer­ences. ­Systemic tol­er­ability was ­also sim­i­larly ­good in the two ­groups; ­from the gas­tric tol­er­ability ­point of ­view, on the con­trary, the ­once-a-day admin­is­tra­tion ­scheme was decid­edly ­better tol­er­ated, ­since no ­patient com­plained of ­local ­adverse man­i­fes­ta­tions, ­against ­slight and tran­sient epi­sodes (epi­gas­tralgia: 3 ­cases, epi­gas­tralgia and ­nausea: 1 ­case) ­detected in the com­par­ison ­group.

top of page